isct annual meeting 18 may 2011 · • aatb • aabb • fda • phac assisted reproduction • us...
TRANSCRIPT
0
SOHO V&S Vigilance and Surveillance of Substances of Human
Origin
(A project co-funded by the EU Programme of Community Action in the Field of Health)
ISCT ANNUAL MEETING18 MAY 2011
Dr Fewzi TeskratSpecial advisor for Human Products
SOHO V&S WP 5 Vigilance in ART
Inspections and Companies DepartmentAFSSAPS
1
General Aim of the Project:General Aim of the Project:
To support EU Member States in theTo support EU Member States in the establishment of effective Vigilance &
Surveillance systems for tissues and cells used in transplantation and in assisted
reproduction.
2
SOHO V&SSpecific Objectives
1. To provide guidance to EU Competent Authorities on the investigation and management of Serious Adverseinvestigation and management of Serious Adverse Reactions and Events associated with tissues and cells for transplantation and for assisted reproduction
2 To provide training to EU Competent Authority officers in2. To provide training to EU Competent Authority officers in the investigation and management of Serious Adverse Reactions and Events associated with tissues and cells for transplantation and for assisted reproduction
3. To provide guidance for professionals working in EU hospitals and clinics on their roles and responsibilities in relation to supporting traceability and vigilance of tissues pp g y gand cells for transplantation and assisted reproduction
3
Specific Objectives
4. To increase awareness and transparency among p y gregulators, professionals and the general public regarding risks associated with human tissues and cells and the steps taken to mitigate themcells and the steps taken to mitigate them.
5. To promote global standardisation and p gcommunication in vigilance and surveillance of tissues and cells for transplantation and assisted reproductionreproduction
4
PartnersCo-ordinating Partner: CNT
Steering CommitteeSteering Committee• Donor Action Foundation• Irish Medicines Board Inspectorate Department• National Transplant Organisation (ONT) Spain• National Transplant Organisation (ONT) Spain • Agence de la Biomedecine, France • AFSSAPS, France • National Centre for Tissue and Cell Banking Poland• National Centre for Tissue and Cell Banking Poland • Human Fertilisation and Embryology Authority UK • Human Tissue Authority
World Health Organisation• World Health Organisation
5
Collaborating Partners (26)
• Bulgarian Executive Agency for
• EBMT• EATBAgency for
Transplantation • Danish Medicines Agency• Federal Ministry of Health,
Austria
• EATB• ESHRE• EEBA• WMDA• AATB• Paul Ehrlich Institute,
Germany• Ministry of Health and
Social Welfare, Croatia• Assisted Reproduction
• AATB• AABB• FDA• PHAC• US CDC• Assisted Reproduction
Registry, Italy• Healthcare Products
Inspectorate, the Netherlands
• US CDC• University of Ottawa• University Hospital Bratislava, Slovakia• Public Health Agency, UK• TRIP the Netherlands• Ministry of Health Malta
• Slovenia Transplant• Ministry of Health, Cyprus
• TRIP, the Netherlands
• International Haemovigilance Network (IHN)
6
Planned Project Outputs• Report of a survey of EU V&S systems (CAs)• Guidance Document on V&S in ART in the EU• Enhancement of Eurocet platform to include vigilance• Report on serious adverse reactions in living donorsReport on serious adverse reactions in living donors
of tissues and cells.• Guidance for EU regulators on the detection and
management of Illegal and Fraudulent Activity in g g yTissues and Cells
• Guidance Document on investigation and communication of Serious Adverse Reactions and Events in Tissues and Cells
• Training course model for investigators of Serious Adverse Reactions and Events
• V&S Guidance for Clinical Units
7
SOHOV&S Project ShapeKey Technical Activities
Phase 1: Exploration Phase II: Guidance Phase III: Dissemination and
TrainingWP4 Questionnaire Survey Report g
WP5 ART donor V&S Workshop Guidance
WP1 Eurocet Enhanced Platform
WP5 Review of Living Donor V&S
WP7Guidance
for R l t
ReportWP8
Training Course
WP6 Review of Illegal and Fraudulent Activity
RegulatorsGuidance
WP8Training
Course
WP7 I t ti lWP2
Global V&S ConferenceWP9
Guidance for Cli i l U
WP7 International Workshop on Investigation
and Reporting (Notify)Report
WP9 Consultation with professionals in TEs and
Cinical Users
Clinical Users of Tissues and Cells
8
Objective of Work Package 6
• Review cases of suspected or proven illegalReview cases of suspected or proven illegal and fraudulent activities (IFA) related to tissues and cells
• Develop guidance to aid in detecting / identifying, investigating and managing such situations.
• Draw upon the experience and findings from EU M b St t d thi d t iEU Member States and third countries
9
( )Fraudulent and illegal activity (IFA)
• CoE definition : Illegal and fraudulentCoE definition : Illegal and fraudulent activities in organs, tissues and cells occurs when there is the illicit procurement, preparation, storage, offering, distribution, brokerage, transport or implantation of
ti d llorgans, tissues and cells.
The prevention and détection of IFA is a major issue because of the serious damage that IFA cause to the image of donation and transplantationimage of donation and transplantation.
10
Guidance for Competent Authorities on Illegal and Fraudulent Activity• (Work package 6 - led by AFSSAPS)• 3 meetings since May 2010 (Paris, Dublin, Vienna)• Outline guidance structure agreed
Questionnaire designed for EU Competent• Questionnaire designed for EU Competent Authorities – distributed in July –
• The questionnaire has collected valuable information – information on current practices and enforcement powers– Individual descriptions of instances of IFA with information
on how they were managed by regulators - lessons learned 16 b itt d– 16 cases submitted.
• Drafting group will meet in May 2011 in Vienna.
11
CConsiderations re IFA• Commercial activities which generate an g
important financial gain
• Needs higher than available supplies
• Insufficient inspection of the procurement establishments
• Lack of specific training of the inspectors on IFAIFA
12
CConsiderations re IFA• Insufficient compliance with regulationsInsufficient compliance with regulations
• Insufficient cooperation in the fieldInsufficient cooperation in the field
• Trafficking in tissues is easier• Trafficking in tissues is easier
• Demand for tissues by the pharmaceutical• Demand for tissues by the pharmaceutical industry
13
Ethical aspects re IFA
• Exploitation of vulnerable groups p g p
• Search for unclaimed bodies at morguesg
• Lack of information and consent from next of kin
F l ifi ti f t f• Falsification of consent forms
R i b t f bl• Reimboursement of unreasonnable expenses
14
Ethical aspects re IFA
Payment issuesPayment issues
• Medical teamed ca tea
• Next of kin (e.g. for the burial expenses)
• Personnel at the morgues
• Brokers (in the case of cord blood)
15
Safety and security aspects re IFASafety and security aspects re IFA
• Non respect of donor selection criteria
• Falsification of the donor testing results
Di t ib ti f ti ith t f t d t• Distribution of tissues without safety data
• Lack of a cross-check of donor records with those ot the TE
• Insufficient audit of procurement activities by tissue bank
• Relabelling of products after expiry dateRelabelling of products after expiry date
• Exportation and importation without authorization
16
Analysis and synthesis of the existing documentation• Charter of fundamental rights of the European Union
(2000)
• CoE : The Additional Protocol supplements the• CoE : The Additional Protocol supplements the Council of Europe Convention on Human Rights and Biomedicine (Oviedo) (2004)
• United Nations (Preventing, combating and punishing ( g, g p gtrafficking in human Organs - Report of the Secretary-General) (2006)
17
Analysis and synthesis of the existing documentation• United Nations : The report on Vienna forum to fight
human trafficking (2008)
• CoE : Trafficking in organs tissues and cells and• CoE : Trafficking in organs, tissues and cells and trafficking in human beings and the replies to the questionnaire for Member States on organ and tissue trafficking (2009)trafficking (2009)
• WHO : Resolutions and decisions of the Executive Board for Human organ and tissue transplantation (2009)*
18
Aims of the questionnaire• To identify the legislative & operational tools that y g p
support Competent Authorities in this area
• To gather information about nature & extent of IFA problem in the European Union
• Scope - Directive 2004/23/EC on tissues & cells used in transplantation & assisted reproductionused in transplantation & assisted reproduction
19
QuestionnaireTo the Competent Authorities of EU Member StatesTo the Competent Authorities of EU Member States
Legislation in place at Member State levelMember State level
Measures in place at CA level
Experience with IFA of tissues and cellstissues and cells
20
P li i Fi diPreliminary Findings
32 Countries responded32 Countries responded
27 EU Member States5 Others
21
Instances of IFA- contacts with CAs
– How the fraudulent activity was detectedHow the fraudulent activity was detected
– How the situation has been managedHow the situation has been managed
What action was taken (penalties others )– What action was taken (penalties, others,..)
What was the follow up and results– What was the follow up and results
22
OOther contacts
Contacts and meeting with others officialContacts and meeting with others official instances
- Europol/Interpol
- justice (Eurojust)j ( j )
(sharing experiences on other types of IFA)(sharing experiences on other types of IFA)
23
IFA CasesTissue / cell /
No Cause of suspicion How detected / identified/
Cord blood / Cord blood stem cells/
6 • Serious adverse eventreported
• Brochures distributed to
• Use of ‘customer’ to inquire aboutthe service and personnel admittedthis service provided for a while.stem cells/
cord tissue Brochures distributed to clinics
• Alerted by a civilian
this service provided for a while.• Not part of Directory of locally
licensed establishments• Serious adverse event reported to
established reporting system• Unable to verify the source of stem
cellsBones 3 • Complaint by recipients • Following site inspectionBones 3 • Complaint by recipients
• Information provided by a former member of establishment
• Following site inspection• After reviewing patient records• Interviews with person involved in
procurement• Interviews with person responsible
for exportation of products
24
IFA CasesTissue / cell / N
oCause of suspicion How detected / identified
Musculoskele 1 Questionable records • Inspections and interviews atMusculoskeletal tissue
1 Questionable records • Inspections and interviews atrecovery site
• Examination of donor records
Gametes / embryos / oocytes / Sperm cells.
4 • Payment of eggdonors from thirdcountry
f
Examination of donor recordsDonor interviews
Sperm cells. • Recurrent use ofsame donors fromthird countriesN li ti f• No application forsite authorisation
None reported
13p
25
CAdvice to the CAs• Avoiding manipulation by the pressAvoiding manipulation by the press
• Avoiding manipulation by stakeholdersAvoiding manipulation by stakeholders
• Care in handling information (cross check)• Care in handling information (cross check)
• Awareness of « business intelligence »• Awareness of « business intelligence »
26
27
Acknowledgements
• Frances Delaney (Afssaps project advisor)Frances Delaney (Afssaps project advisor)
• Deirdre Fehily (CNT)• Deirdre Fehily (CNT)
• Teena Chowdhury (HTA)• Teena Chowdhury (HTA)
Type tissue / cell involvd
Suspicion /Issue How detected / identified
Prescribed activity involved
Who investigated Final outcome
Cord blood Local procurement Brochures of import Police Pending court
28
Cord blood Local procurement and storage in another MS in a non‐licensed TE
Brochures of Establishment were distributed to Clinics
Competent
import Police Pending court decision for prosecution
Competent authority contacted the CA of the MS that the cord blood was stored. Verified the absence of License
Cord blood Brought to the attention of inspectorate by civilian
Applied for licensing the activity after CA enquired about such activity
Activity involved procurement, testing, processing, storage
CA and police Pending court decision
y
Before CA enquiry to the TE, we used dummy customer to inquire about this
g
service and the TE personnel admitted that they provide this service for a while.
bones Complains from Complain from Import By the police and The importer has
29
bones Complains from patients who have been affected after transplantation (quality defect of the final products)
Complain from many recipient
After reviewing the patient records• no medical
Import By the police and CA (inspection done on sites)
The importer has been judged and put in jail and has been obliged to pay a important amount of money p )
record of the procurement
establishment• serological
test were
yto the justice
missing or not done
• quality defect of the bones after surgery which injured and affected many patients
use of bones after expiry date
no traceability data
Musculoske CA notified by one Inspection Tissue Recovery – CA + police Procurement
30
letal tissue, including bone and skin
of the processors who received tissue recovered by this firm. The processor had questions
conducted at the recovery firm. Inspectors interviewed the president/owner
tissues were being recovered without adequate donor screening and testing.
organization team have been put in jail
regarding the records provided by the recovery firm. For example, the telephone numbers f h d ’
and several employees, obtained statements and collected donor
d d hof the donors’ physicians were incorrect for over 25 donors.
records and other relevant evidence. Investigators also performed inspections at
l f lseveral funeral homes involved in the case, and obtained death certificates from State and localState and local authorities.
31
SO O & SSOHO & VS
Th k f tt tiThank you for your attention